Epicutaneous aeroallergen exposure induces systemic TH2 immunity that predisposes to allergic nasal responses - 17/08/11
Cincinnati, Ohio
Abstract |
Background |
Atopic individuals are predisposed to mounting vigorous TH2-type immune responses to environmental allergens. The skin is often the first organ that manifests allergic disease and may provide an early entry point for antigen sensitization.
Objective |
We sought to determine whether epicutaneous exposure to the aeroallergen Aspergillus fumigatus induces nasal allergic responses. Furthermore, we aimed to examine the mechanism involved.
Methods |
Wild-type and signal transducer and activator of transcription 6 (STAT6)–deficient mice were exposed to epicutaneous A fumigatus and control antigen ovalbumin. Nasal inflammation and responsiveness to methacholine were monitored.
Results |
Exposure to epicutaneous A fumigatus antigen induced a marked atopic dermatitis-like phenotype in a manner significantly more efficient than epicutaneous ovalbumin. A single A fumigatus intranasal challenge induced clinical nasal responses and hyperresponsiveness to methacholine in the nose as manifested by nasal symptoms, accompanied by allergic airway and nasal inflammation. Mechanistic analysis using gene-targeted mice revealed that the clinical nasal responses and hyperresponsiveness were STAT6-dependent. Although STAT6 was required for changes in nasal responses, it was not required for epicutaneous pathology except eosinophilia.
Conclusion |
Epicutaneous exposure to the aeroallergen A fumigatus potently primes for STAT6-dependent nasal responses. These results draw attention to the cooperative interaction between the nasal tract and skin.
Clinical implications |
The skin is a potent site for antigen sensitization in the development of experimental allergic rhinitis.
Le texte complet de cet article est disponible en PDF.Key words : Allergy, atopic, dermatitis, eosinophilia, epicutaneous, lung, nose, sensitization, STAT6
Abbreviations used : AD, AHR, Penh, STAT6
Plan
Supported by National Institutes of Health grants R01 AI42242, HL-076383 and AI057803 (to Dr Rothenberg). Disclosure of potential conflict of interest: M. E. Rothenberg has consultant arrangements with GlaxoSmithKline and Ception Therapeutics, owns stock in Ception Therapeutics, has received grant support from Cambridge Antibody Technology, and is on the speakers’ bureau for Merck. The rest of the authors have declared that they have no conflict of interest. |
Vol 118 - N° 1
P. 62-69 - juillet 2006 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?